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Background: Therapeutic angiogeneisis is a clinically effective strategy for patients with peripheral artery disease (PAD). Autologous bone marrow 
mononuclear cell is commonly used cell source in Japan. However it is still unknown whether local therapeutic angiogenesis could improve systemic 
vascular function after treatment. Also the mechanism is complicated because aoutologous bone marrow mononuclear cells secrete variable 
substances in response to ischemia. The purpose of this study was to determine whether single growth factor, basic fibroblast growth factor (b-FGF) 
administration improves systemic vascular function in patients with PAD. 
Methods: Limb ischemia was confirmed by digital subtraction angiography. After screening for preexisting coronary artery disease, cerebrovascular 
disease and malignancy, PAD patients suffering Fontaine class 3 or 4 were enrolled (n = 12, 56 ± 17 y/o). Gelatin hydrogel containing 600 μg of 
b-FGF, which is control release formula of b-FGF, was administered into the ischemic limbs. Transcutaneous oxygen tension (TcPO2) was examined 
to evaluate skin perfusion. Also, 99mTc-tetrofosmin scintigraphy was performed to examine tissue blood flow. Non-invasive endothelial function 
was determined by brachial artery endothelial-dependent flow - mediated dilatation (FMD) and endothelial-independent glyceryl trinitrate (GTN) - 
mediated dilatation before and 4 weeks after treatment. 
Results: b-FGF administration improved visual analog pain scale (72.9 ± 26 to 6.8 ± 12, P < 0.01) and TcPO2 (14.7 ± 14 to 47.3 ± 16 mmHg, P < 
0.01) at ischemic limbs 4 weeks after treatment. 99mTc-tetrofosmin scintigraphy score from opposite side (non-treated limbs) tend to be improved 
(0.64 ± 0.3 to 0.75 ± 0.3, P = 0.37), however it was not reached to the statistical significance. Compared to this, FMD was significantly improved 
(3.94 ± 1.4 to 7.83 ± 2.8 %, P < 0.01) at 4 weeks after the treatment. Endothelial-independent GTN mediated dilatation was not altered (8.8 ± 3.8 
to 10.2 ± 4.9 %, NS). 
Conclusions: These findings suggest that local therapeutic angiogenesis, which induced by slow-released b-FGF, may restore systemic 
endothelium-dependent vasodilation in patients with PAD.
